Q-omics provides the consensus-scored NCOA7 profile across patient tissues and cancer cell-line models. NCOA7 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, NCOA7 is differentially expressed in 14, with the highest sampling consensus in KIRC. Additionally, NCOA7 protein abundance shows 40,835 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRC, and GBM as cancer lineages where NCOA7 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NCOA7 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NCOA7 survival associations across molecular data types. NCOA7 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (9) and mass-spec protein abundance (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NCOA7 RNA expression–survival associations across cancer types. High NCOA7 expression shows unfavorable associations in KIRP, UCEC, CESC and DLBC, but favorable associations in KIRC and SKCM. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for NCOA7 RNA expression.
This table summarizes NCOA7 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 13. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for NCOA7. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NCOA7 shows lower tumor expression in KIRC, KICH, BLCA, LUSC and KIRP and higher tumor expression in STAD. The KIRC box plot shows higher NCOA7 RNA expression in normal versus tumor tissue (log2 FC = −1.152, t-test p < 0.001).
This table shows molecular features associated with NCOA7 in patient tissues and cancer cell lines. In patient samples, NCOA7 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, NCOA7 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and BREAST.
